{"id":1452,"date":"2013-05-19T16:24:01","date_gmt":"2013-05-19T14:24:01","guid":{"rendered":"http:\/\/viscontitoscoalda.com\/?p=1452"},"modified":"2013-05-19T16:24:01","modified_gmt":"2013-05-19T14:24:01","slug":"cannabis-terapeutica-sativex-approvato","status":"publish","type":"post","link":"https:\/\/viscontitoscoalda.com\/index.php\/2013\/05\/19\/cannabis-terapeutica-sativex-approvato\/","title":{"rendered":"Cannabis terapeutica: Sativex approvato…"},"content":{"rendered":"

Cannabis approvato spray per ridurre i sintomi nella sclerosi multipla<\/a><\/p>\n

copia incolla dal sito: Cannabis approvato spray contro… <\/a><\/p>\n

premesso che\u00a0 il Sativex, come gli altri farmaci cannabinoidi, non \u00e8 contro la Sclerosi Multipla e quindi non deve creare false illusioni, \u00e8 un farmaco che viene utilizzato per ridurre i sintomi del dolore\u00a0 e della spasticit\u00e0 nella Sclerosi Multipla e in molte altre patologie che presentano le stesse problematiche. Mi sono permessa di utilizzare la fonte, in quanto \u00e8 stato ben inserito tutto il contesto per la presentazione del farmaco che diversi ammalati stanno aspettando, pur dissentendo sul titolo, per non creare appunto false speranze.<\/p>\n

Cannabis approvato spray contro la spasticit\u00e0 da sclerosi multipla<\/h5>\n
\n
\n
maggio 8, 2013<\/span> by carmagnola<\/a>
\nFiled under CANNABIS MEDICA<\/a>,<\/h6>\n
NEWS ITALIA<\/a>,<\/h6>\n
SCLEROSI MULTIPLA<\/a><\/h6>\n<\/div>\n
\n

<\/span><\/p>\n<\/div>\n<\/div>\n

Una buona notizia per i tanti malati italiani di sclerosi multipla che soffrono di problemi di spasticit\u00e0. Anche nel nostro Paese \u00e8 stato approvato uno spray oro mucosale indicato per il trattamento della spasticit\u00e0\u00a0 da moderata a grave.<\/p>\n

Il farmaco \u00e8 indicato per i pazienti che soffrono di spasticit\u00e0 da sclerosi multipla non adeguatamente controllata dagli antispastici classici. La decisione di Aifa \u00e8 stata pubblicata in Gazzetta Ufficiale e il farmaco \u00e8 rimborsato dal Ssn in Classe H. A partire dal mese di settembre, sar\u00e0 progressivamente disponibile presso le Farmacie Ospedaliere dei Centri di Sclerosi Multipla .<\/p>\n

Il prodotto, che sar\u00e0 messo in commercio da Almirall con il marchio Sativex,\u00a0contiene due cannabinoidi: THC (delta-9-tetraidrocannabinolo) e CBD (cannabidiolo).\u00a0 Si tratta della prima medicina derivata dalla pianta di Cannabis sativa, coltivata e lavorata in condizioni rigidamente controllate.<\/p>\n

Il farmaco \u00e8 un medicinale soggetto a prescrizione medica ed \u00e8 stato sviluppato dalla societ\u00e0 GW Pharmaceuticals per alleviare i sintomi della spasticit\u00e0, in pazienti con SM, che includono: rigidit\u00e0 muscolare, crampi e spasmi dolorosi, disfunzioni della vescica e disturbi del sonno. Il nuovo farmaco \u00e8 privo degli effetti collaterali che derivano dal consumo di cannabis non a fini terapeutici e non crea dipendenza.<\/p>\n

Spasticit\u00e0 significa aumento del normale tono muscolare a riposo. \u00c8 un sintomo frequente nella sclerosi multipla, presente in oltre tre quarti dei pazienti totali, molto spesso si associa a debolezza muscolare. La spasticit\u00e0 contribuisce, in maniera sostanziale, alla disabilit\u00e0 associata all\u2019evolversi di questa malattia.<\/p>\n

Essa comporta una rigidit\u00e0 muscolare e un deficit di forza che limitano i movimenti di un arto. Nella SM gli arti inferiori sono pi\u00f9 affetti da questo sintomo che si pu\u00f2 associare anche a spasmi dolorosi. In alcuni pazienti per\u00f2 la aumentata rigidit\u00e0 muscolare in estensione a carico dei quadricipiti \u00e8 un vantaggio ai fini della capacit\u00e0 di mantenersi in piedi e deambulare, perch\u00e9 supplisce in parte alla debolezza muscolare. Comunque si possono verificare improvvisi cali del tono muscolare.<\/p>\n

fonte: www.pharmastar.it<\/a><\/p>\n

per info: Dossier AISM sui cannabinoidi nella sclerosi multipla<\/a><\/p>\n

<\/span><\/p>\n

Arrivano i farmaci cannabinoidi; no, non arrivano<\/span><\/strong><\/p>\n

fonte: http:\/\/www.aduc.it<\/a><\/p>\n

Articolo di Francesco Crestani *<\/strong><\/p>\n

Apprendiamo con sgomento che l\u2019Agenzia Italiana del Farmaco AIFA ha rilasciato l\u2019autorizzazione all\u2019immissione al commercio al farmaco Sativex, cio\u00e8 al primo farmaco cannabinoide sul mercato italiano.
\nSe il nostro sgomento sembra paradossale, visto che la nostra associazione da anni si batte affinch\u00e8 questi farmaci siano finalmente disponibili per i medici e i malati italiani, vogliamo evidenziare quali limiti l\u2019AIFA ha posto alla loro prescrivibilit\u00e0.
\nIl Sativex, spray orale derivato dalla pianta della Cannabis, \u00e8 prescrivibile \u201cliberamente\u201d alle seguenti condizioni:
\nper un\u2019unica patologia, la sclerosi multipla;
\nma non per tutti i malati di sclerosi multipla, solo quelli affetti da spasmi;
\nma solo dopo aver provato tutti gli altri farmaci disponibili;
\nma solo su prescrizione di centri ospedalieri o di specialisti-neurologo (sic);
\nma il medico proscrittore dovr\u00e0 registrare online sul sito dell\u2019AIFA la sua prescrizione, comprensiva dei suoi dati e di quelli del paziente, cos\u00ec da essere \u201cmonitorato\u201d (e sottolinea letteralmente l\u2019AIFA, sar\u00e0 sua responsabilit\u00e0 , del medico, prescrivere secondo tali regole, onde evitare accuratamente che altre categorie di malati possano beneficiare di tali farmaci).
\nTale decisione peraltro avviene solo pochi giorni dopo che finalmente era nuovamente disponibile in Italia il farmaco galenico, cio\u00e8 l\u2019infiorescenza prodotta sotto il controllo del Ministero della salute olandese, virtualmente prescrivibile finora da parte di qualsiasi medico e per qualsiasi patologia. I solerti funzionari dell\u2019AIFA hanno pensato anche a questo: infatti tutti questi farmaci galenici, detti anche magistrali, cio\u00e8 preparati in farmacia a partire dalla pianta, dovranno seguire le stesse limitazioni del Sativex.
\nL\u2019AIFA in questo modo potr\u00e0 affermare che oggi anche in Italia sono disponibili i farmaci a base di Cannabis, mentre questo regime di dispensazione in pratica disinnesca una bomba che stava per scoppiare. Infatti non era pi\u00f9 possibile aspettare oltre l\u2019arrivo di tali medicinali, ormai presenti in molti paesi, dagli USA al Canada, dall\u2019Olanda alla Repubblica Ceca, dalla Spagna a Israele tanto per dirne alcuni, e si tratta di paesi dai sistemi sanitari certamente molto avanzati.
\nQuello che \u00e8 incomprensibile \u00e8 che l\u2019AIFA, che dovrebbe essere un organismo scientifico, non ha nemmeno seguito le linee guida delle Societ\u00e0 Europee di Neurologia, pubblicate gi\u00e0 nel 2006 e rivedute nel 2009. Tali linee guida prevedono i cannabinoidi per il dolore neuropatico da sclerosi multipla, pur come farmaci di seconda linea (peraltro tale rassegna dimostra che i cannabinoidi posseggono un\u2019evidenza di efficacia maggiore rispetto a tutti gli altri farmaci di uso comune). Lo stesso articolo riporta che pure nel dolore neuropatico da AIDS la cannabis ha un\u2019evidenza di efficacia di livello A, cio\u00e8 scientificamente la maggiore. Lo stesso vale per il dolore neuropatico a eziologia multipla. In tutte queste patologie la rassegna dimostra che i cannabinoidi migliorano non solo il dolore, ma anche la qualit\u00e0 della vita e il sonno dei malati.
\nNon si \u00e8 tenuto nemmeno conto che in Canada, dove il Sativex \u00e8 disponibile da vari anni, esso \u00e8 indicato anche per il dolore da cancro. E non si comprende per quale motivo le limitazioni riguardanti il Sativex debbano obbligatoriamente essere applicate anche agli altri medicinali cannabinoidi, come quelli di \u201ctipo olandese\u201d, visto che nei Paesi Bassi, come riporta il sito elaborato dal locale Ministero della salute, tali farmaci sono presentati cos\u00ec: \u201cI dati attualmente disponibili dimostrano che i cannabinoidi possono aiutare a ridurre: i dolori e gli spasmi muscolari \/ crampi associati alla sclerosi multipla o a danni al midollo spinale; la nausea, la riduzione dell\u2019appetito, la perdita di peso e la debilitazione associati con il cancro e l\u2019AIDS; la nausea e il vomito indotti da farmaci o radioterapia per il cancro e l\u2019HIV \/ AIDS; il dolore neurogeno di lunga durata causato, per esempio, da danni ai nervi, il dolore dell\u2019arto fantasma, la nevralgia facciale o dolore cronico a seguito di un attacco di herpes zoster; i tic associati con la sindrome di Tourette; il glaucoma resistente alla terapia\u201d Riporta ancora il sito ufficiale dell\u2019Ufficio per la cannabis medica olandese: \u201cAttualmente, la cannabis medicinale non pu\u00f2 curare le condizioni di cui sopra. Si pu\u00f2, tuttavia, alleviare i sintomi associati con esse, e \/ o ridurre gli effetti collaterali di altri farmaci. Spetta ai medici di determinare quali condizioni potrebbero trarre beneficio dal trattamento con la cannabis medicinale, e in quali circostanze sarebbe giusto per il paziente. In tal modo essi non sono limitati alla lista delle caratteristiche sopra indicate.\u201d
\nQuesto \u201cdecreto\u201d dell\u2019AIFA blocca in pratica lo sviluppo della produzione di cannabis terapeutica in Italia, quando sappiamo che esiste gi\u00e0 un istituto di ricerca pubblico, il Cracin di Rovigo, che coltiva cannabis di altissima qualit\u00e0 farmacologica. Ma periodicamente, e paradossalmente, chili di prodotto, che potrebbero servire a curare un gran numero di pazienti a costo estremamente ridotto (mentre il Sativex costa centinaia di euro a flacone) vengono sequestrati dalla Guardia di Finanza e distrutti.
\nQuesto \u201cdecreto\u201d tarpa tutte le regioni che si erano dotate di strumenti legislativi appositi per venire incontro alle esigenze di medici e pazienti.
\nQuesto \u201cdecreto\u201d strappa i farmaci a tutti quei pazienti, non affetti da sclerosi multipla, che in questi anni erano riusciti ad ottenere medicinali cannabinoidi di importazione, e si ritrovano da un giorno all\u2019altro nell\u2019impossibilit\u00e0 di proseguire l\u2019unica cura che si era dimostrata efficace, dopo averle provate tutte.
\nQuesto \u201cdecreto\u201d annulla la speranza di tanti malati affetti da gravi patologie non responsive alle usuali terapie, speranza non fideistica, ma basata sulle conoscenze scientifiche che via via si accumulano ogni giorno sul sistema endocannabinoide, che regola molte funzioni del nostro organismo. Speranza basata inoltre su studi clinici controllati effettuati in diverse malattie, dalla fibromialgia ai danni del midollo, dall\u2019epilessia al morbo di Crohn tanto per citarne alcune.
\nE questo \u201cdecreto\u201d impedisce ai medici di poter dare un aiuto ai propri pazienti e di poter contare su un\u2019arma in pi\u00f9 nella lotta contro la sofferenza.<\/p>\n

* presidente ACT, associazione per la cannabis terapeutica<\/a><\/p>\n

—————————————————————-<\/p>\n

Cannabis approved spray against spasticity from multiple sclerosis<\/p>\n

May 8, 2013 by carmagnola
\nFiled under CANNABIS MEDICAL NEWS ITALY, MULTIPLE SCLEROSIS<\/p>\n

Good news for the many sick people of Italian multiple sclerosis who suffer from problems with spasticity. Even in our country has been approved gold mucosal spray indicated for the treatment of moderate to severe spasticity.<\/p>\n

The drug is indicated for patients who suffer from spasticity in multiple sclerosis is not adequately controlled with antispasmodics classics. The AIFA decision was published in the Official Gazette and the drug is reimbursed by the NHS in the class H. Starting in September, will be progressively available at the Hospital Pharmacies of Multiple Sclerosis Centers.<\/p>\n

The product, which will be marketed by Almirall under the brand name Sativex contains two cannabinoids: THC (delta-9-tetrahydrocannabinol) and CBD (cannabidiol). This is the first medicine derived from the plant Cannabis sativa, grown and processed under strictly controlled conditions.<\/p>\n

The drug is a medicinal product subject to medical prescription and was developed by GW Pharmaceuticals to alleviate the symptoms of spasticity in patients with MS, which include: muscle stiffness, cramps and painful spasms, bladder dysfunction and sleep disorders. The new drug is devoid of the side effects that result from the consumption of cannabis for therapeutic purposes and is not addictive.<\/p>\n

Spasticity means an increase of the normal resting muscle tone. It is a common symptom in multiple sclerosis is present in over three-quarters of total patients, very often associated with muscle weakness. Spasticity contributes substantially, disability associated with the evolution of this disease.<\/p>\n

It involves a muscle rigidity and a strength deficit which restrict the movement of a limb. In MS, the lower limbs are more affected by this symptom that can be associated also with painful spasms. In some patients, however, the increased muscle stiffness in extension with the quadriceps is an advantage in the ability to remain standing and ambulation, because it compensates in part to muscle weakness. However, you may encounter sudden drops in muscle tone.<\/p>\n

source: www.pharmastar.it<\/p>\n

Dossier AISM sui cannabinoidi nella sclerosi multipla<\/a><\/p>\n

Here come the cannabinoid drugs, no, do not come<\/p>\n

source: http:\/\/www.aduc.it<\/a><\/p>\n

Article by Francesco Crestani *<\/p>\n

We learn with dismay that the Italian medicines agency AIFA has granted authorization to market the drug Sativex, ie, the first cannabinoid medicine in the Italian market.
\nIf our dismay it seems paradoxical, given that our association has been fighting for these drugs are now available for physicians and patients Italian, we want to highlight what limits the AIFA has placed on their prescribing.
\nThe Sativex oral spray derived from the Cannabis plant, can be prescribed “freely” to the following conditions:
\nfor a single disease, multiple sclerosis;
\nbut not for all sufferers of multiple sclerosis, only those with spasms;
\nbut only after having tried all the other available drugs;
\nbut only on prescription hospitals or specialist-neurologist (sic);
\nbut the physician prescriber must register online at AIFA his prescription, including its data and those of the patient, so as to be “monitored” (literally and stresses the AIFA shall be its responsibility, the physician, according to prescribe such rules, in order to carefully avoid that other categories of patients can benefit from these drugs).
\nThis decision, however, is only a few days later that it was finally available again in Italy on drug pharmaceutics, ie the inflorescence produced under the control of the Dutch Ministry of Health, so far virtually be prescribed by any doctor and any disease. The zealous of the AIFA have thought of that: in fact, all these drugs Galen, also called masterful, that is prepared in a pharmacy from the plant will follow the same limitations of Sativex.
\nThe AIFA in this way can also be said that today in Italy is available cannabis-based drugs, while this regime dispensing practice defuse a bomb that was about to burst. In fact it was no longer possible to wait any longer for the arrival of these products, now present in many countries, from the USA to Canada, from the Netherlands to the Czech Republic, Spain to Israel to name a few, and it is certainly countries by health systems very advanced.
\nWhat is incomprehensible is that the AIFA, which should be a scientific body, has not even followed the guidelines of the European Society of Neurology, published in 2006 and revised in 2009. These guidelines set out the cannabinoids for neuropathic pain from multiple sclerosis, even as a second-line drugs (though this exhibition demonstrates that cannabinoids possess evidence of greater effectiveness than all other drugs in common use). The same article also reports that in neuropathic pain from AIDS cannabis has evidence of the effectiveness of level A, that is scientifically more. The same is true for neuropathic pain in multiple etiology. In all these diseases the review demonstrates that cannabinoids improve not only the pain, but also the quality of life and the sleep of the sick.
\nWas not taken into account that even in Canada, where Sativex has been available for several years, it is also indicated for cancer pain. It is not understood why the limitations on the Sativex be required to be applied to other cannabinoid drugs, such as those of “Dutch type”, as in the Netherlands, as reported by the website developed by the local Ministry of Health, these drugs are presented as follows: “Currently available data show that cannabinoids can help reduce: the pain and muscle spasms \/ cramps associated with multiple sclerosis or spinal cord damage, nausea, decreased appetite, weight loss and debilitation associated with cancer and AIDS; nausea and vomiting induced by drugs or radiotherapy for cancer and HIV \/ AIDS, and the long-lasting nerve pain caused, for example, from nerve damage, pain dell ‘ phantom limb, the facial neuralgia or chronic pain following a shingles attack; tics associated with Tourette’s syndrome, glaucoma therapy-resistant “It still bears the official website of the Office for the Dutch medical cannabis:” Currently, medicinal cannabis can not cure the conditions above. It can, however, relieve the symptoms associated with them, and \/ or reduce the side effects of other medications. It is up to doctors to determine what conditions might benefit from treatment with medicinal cannabis, and under what circumstances it would be right for the patient. In this way they are not limited to the list of characteristics indicated above. ”
\nThis “decree” AIFA locks into practice the development of production of cannabis in Italy, when we know that there is already a public research institute, the Cracin of Rovigo, who grows cannabis high quality medication. But periodically, and, paradoxically, pounds of product, which could be used to treat a large number of patients at very low cost (while Sativex costs hundreds of Euros per bottle) are seized by the Guardia di Finanza and destroyed.
\nThis “decree” whittled away all the regions that were equipped with the appropriate legislative instruments to meet the needs of doctors and patients.
\nThis “decree” ripping drugs to all patients, not suffering from multiple sclerosis, which in recent years had been able to obtain import of medicinal cannabis, and find themselves almost overnight it impossible to continue the only treatment that had proved effective, after having tried everything.
\nThis “decree” undo hope to many patients suffering from serious diseases unresponsive to usual therapies, fideistic hope not, but based on the scientific knowledge that gradually accumulate every day on the endocannabinoid system, which regulates many functions of our body. Hope also based on controlled clinical studies in different diseases, fibromyalgia from the damage of the bone, from epilepsy to Alzheimer’s disease to name a few.
\nAnd this “decree” prevents doctors to be able to give help to their patients and to be able to count on one more weapon in the fight against suffering.<\/p>\n

*ACT President, associazione per la cannabis terapeutica<\/a> ACT President, Association for cannabis<\/p>\n

Cannabis approuv\u00e9 pulv\u00e9risation contre la spasticit\u00e9 de la scl\u00e9rose en plaques<\/span><\/span><\/p>\n

8 mai 2013 par carmagnola
\n<\/span>Filed under CANNABIS MEDICAL NOUVELLES ITALIE, LA SCL\u00c9ROSE EN PLAQUES<\/span><\/p>\n

Laisser un commentaire<\/span><\/p>\n

Bonnes nouvelles pour les nombreux malades de la scl\u00e9rose en plaques italien qui souffrent de probl\u00e8mes de spasticit\u00e9. <\/span>Pulv\u00e9risation muqueuse or M\u00eame dans notre pays a \u00e9t\u00e9 approuv\u00e9 indiqu\u00e9 pour le traitement des formes mod\u00e9r\u00e9es \u00e0 spasticit\u00e9 s\u00e9v\u00e8re.<\/span><\/p>\n

Le m\u00e9dicament est indiqu\u00e9 pour les patients qui souffrent de spasticit\u00e9 dans la scl\u00e9rose en plaques n’est pas suffisamment contr\u00f4l\u00e9e avec des classiques antispasmodiques. <\/span>La d\u00e9cision AIFA a \u00e9t\u00e9 publi\u00e9 dans la Gazette officielle et le m\u00e9dicament est rembours\u00e9 par le NHS dans la classe H. <\/span>A partir de Septembre, seront progressivement disponibles dans les pharmacies hospitali\u00e8res des centres de scl\u00e9rose en plaques.<\/span><\/p>\n

Le produit, qui sera commercialis\u00e9 par Almirall sous le nom de Sativex contient deux cannabino\u00efdes: le THC (delta-9-t\u00e9trahydrocannabinol) et le CBD (cannabidiol). <\/span>C’est le premier m\u00e9dicament d\u00e9riv\u00e9 du Cannabis sativa usine, cultiv\u00e9s et transform\u00e9s dans des conditions strictement contr\u00f4l\u00e9es.<\/span><\/p>\n

Le m\u00e9dicament est un m\u00e9dicament soumis \u00e0 prescription m\u00e9dicale et a \u00e9t\u00e9 d\u00e9velopp\u00e9 par GW Pharmaceuticals pour soulager les sympt\u00f4mes de la spasticit\u00e9 chez les patients atteints de SEP, qui incluent: la raideur musculaire, des crampes et des spasmes douloureux, le dysfonctionnement de la vessie et des troubles du sommeil. <\/span>Le nouveau m\u00e9dicament est d\u00e9pourvu des effets secondaires qui r\u00e9sultent de la consommation de cannabis \u00e0 des fins th\u00e9rapeutiques et n’est pas addictive.<\/span><\/p>\n

La spasticit\u00e9 signifie une augmentation du tonus musculaire normal de repos. <\/span>Il est un sympt\u00f4me fr\u00e9quent dans la scl\u00e9rose en plaques est pr\u00e9sent dans plus des trois quarts du total des patients, tr\u00e8s souvent associ\u00e9s \u00e0 une faiblesse musculaire. <\/span>La spasticit\u00e9 contribue de mani\u00e8re substantielle, le handicap associ\u00e9 \u00e0 l’\u00e9volution de cette maladie.<\/span><\/p>\n

Il s’agit d’une rigidit\u00e9 musculaire et un d\u00e9ficit de force qui limitent le mouvement d’un membre. <\/span>Dans la SEP, les membres inf\u00e9rieurs sont plus touch\u00e9s par ce sympt\u00f4me qui peut \u00eatre \u00e9galement associ\u00e9e \u00e0 des spasmes douloureux. <\/span>Chez certains patients, cependant, l’augmentation de la raideur musculaire en extension avec le quadriceps est un avantage dans la capacit\u00e9 de rester debout et de la marche, car elle compense en partie \u00e0 la faiblesse musculaire. <\/span>Toutefois, vous pouvez rencontrer des baisses soudaines du tonus musculaire.<\/span><\/p>\n

Source: www.pharmastar.it<\/span><\/p>\n

pour info: Dossier AISM sur les cannabino\u00efdes dans la scl\u00e9rose en plaques<\/span><\/p>\n

Voici venir les m\u00e9dicaments cannabino\u00efdes, non, ne venez pas<\/span><\/p>\n

Source: http:\/\/www.aduc.it<\/span><\/p>\n

Article par Francis Crestani *<\/span><\/p>\n

Nous apprenons avec consternation que l’Italien m\u00e9dicaments agence AIFA a accord\u00e9 l’autorisation de commercialiser le m\u00e9dicament Sativex, c’est le premier m\u00e9dicament cannabino\u00efde sur le march\u00e9 italien.
\n<\/span>Si notre grande consternation, il semble paradoxal, \u00e9tant donn\u00e9 que notre association se bat depuis ces m\u00e9dicaments sont d\u00e9sormais disponibles pour les m\u00e9decins et les patients italiens, nous voulons mettre en \u00e9vidence ce qui limite l’AIFA a mis sur leur prescription.
\n<\/span>Le spray buccal Sativex d\u00e9riv\u00e9 de la plante de cannabis, peut \u00eatre prescrit “librement” aux conditions suivantes:
\n<\/span>pour une seule maladie, la scl\u00e9rose en plaques;
\n<\/span>mais pas pour toutes les personnes atteintes de scl\u00e9rose en plaques, seuls ceux qui ont des spasmes;
\n<\/span>mais seulement apr\u00e8s avoir essay\u00e9 toutes les autres m\u00e9dicaments disponibles;
\n<\/span>mais seulement sur les h\u00f4pitaux de prescription ou sp\u00e9cialiste-neurologue (sic);
\n<\/span>mais le prescripteur du m\u00e9decin doit s’inscrire en ligne \u00e0 AIFA son ordonnance, y compris ses donn\u00e9es et celles du patient, de mani\u00e8re \u00e0 \u00eatre “surveill\u00e9” (litt\u00e9ralement et souligne l’AIFA est sa responsabilit\u00e9, le m\u00e9decin, selon de prescrire tel <\/span>r\u00e8gles, afin d’\u00e9viter soigneusement que d’autres cat\u00e9gories de patients peuvent b\u00e9n\u00e9ficier de ces m\u00e9dicaments).
\n<\/span>Cette d\u00e9cision, cependant, est que quelques jours plus tard qu’il \u00e9tait enfin disponible \u00e0 nouveau en Italie sur la pharmacie des m\u00e9dicaments, \u00e0 savoir l’inflorescence fabriqu\u00e9s sous le contr\u00f4le du minist\u00e8re n\u00e9erlandais de la Sant\u00e9, jusqu’ici pratiquement \u00eatre prescrit par un m\u00e9decin et une maladie quelconque. <\/span>Le z\u00e8le de l’AIFA ont pens\u00e9: en fait, tous ces m\u00e9dicaments Galien, aussi appel\u00e9s magistrale, qui est pr\u00e9par\u00e9 en pharmacie de l’usine suivra les m\u00eames limites de Sativex.
\n<\/span>L’AIFA de cette mani\u00e8re peut aussi dire qu’aujourd’hui en Italie m\u00e9dicaments disponibles \u00e0 base de cannabis, alors que ce r\u00e9gime de distribution pratique d\u00e9samorcer une bombe qui \u00e9tait sur le point d’\u00e9clater. <\/span>En fait, il n’\u00e9tait plus possible d’attendre plus longtemps pour l’arriv\u00e9e de ces produits, aujourd’hui pr\u00e9sent dans de nombreux pays, des Etats-Unis au Canada, des Pays-Bas \u00e0 la R\u00e9publique tch\u00e8que, l’Espagne \u00e0 Isra\u00ebl pour n’en nommer que quelques-uns, et il est certainement pays par les syst\u00e8mes de sant\u00e9 <\/span>tr\u00e8s avanc\u00e9.
\n<\/span>Ce qui est incompr\u00e9hensible, c’est que l’AIFA, qui devrait \u00eatre un organe scientifique, n’a m\u00eame pas suivi les directives de la Soci\u00e9t\u00e9 europ\u00e9enne de neurologie, publi\u00e9 en 2006 et r\u00e9vis\u00e9 en 2009. <\/span>Ces lignes directrices \u00e9noncent les cannabino\u00efdes pour la douleur neuropathique de la scl\u00e9rose en plaques, m\u00eame en tant que m\u00e9dicaments de deuxi\u00e8me ligne (bien que cette exposition d\u00e9montre que les cannabino\u00efdes poss\u00e8dent preuve d’une plus grande efficacit\u00e9 que les autres m\u00e9dicaments d’usage courant). <\/span>Le m\u00eame article signale \u00e9galement que dans la douleur neuropathique de cannabis sida a des preuves de l’efficacit\u00e9 de niveau A, ce qui est scientifiquement plus. <\/span>La m\u00eame chose est vrai pour la douleur neuropathique dans l’\u00e9tiologie multiple. <\/span>Dans toutes ces maladies, l’examen d\u00e9montre que les cannabino\u00efdes am\u00e9liorer non seulement la douleur, mais aussi la qualit\u00e9 de vie et le sommeil du malade.
\n<\/span>N’a pas tenu compte du fait que m\u00eame au Canada, o\u00f9 Sativex est disponible depuis plusieurs ann\u00e9es, il est \u00e9galement indiqu\u00e9 pour la douleur canc\u00e9reuse. <\/span>On ne comprend pas pourquoi les limitations sur le Sativex devoir \u00eatre appliqu\u00e9 \u00e0 d’autres m\u00e9dicaments cannabino\u00efdes, tels que ceux de type “hollandais”, comme aux Pays-Bas, tel que rapport\u00e9 par le site Web \u00e9labor\u00e9 par le minist\u00e8re de la Sant\u00e9 local, ces m\u00e9dicaments sont <\/span>pr\u00e9sent\u00e9 comme suit: \u00abActuellement les donn\u00e9es disponibles montrent que les cannabino\u00efdes peuvent aider \u00e0 r\u00e9duire: la douleur et les spasmes musculaires \/ crampes associ\u00e9s \u00e0 la scl\u00e9rose en plaques ou de l\u00e9sions de la moelle \u00e9pini\u00e8re, des naus\u00e9es, perte d’app\u00e9tit, perte de poids et <\/span>debilitation associ\u00e9e au cancer et au SIDA, des naus\u00e9es et vomissements induits par la drogue ou la radioth\u00e9rapie pour le cancer et le VIH \/ SIDA, et la douleur du nerf de longue dur\u00e9e caus\u00e9es, par exemple, de l\u00e9sions nerveuses, des douleurs dell ‘ <\/span>membre fant\u00f4me, la n\u00e9vralgie faciale ou une douleur chronique \u00e0 la suite d’une crise de zona; tics associ\u00e9s avec le syndrome de Tourette, r\u00e9sistante au traitement du glaucome “Elle porte encore le site officiel de l’Office pour le cannabis m\u00e9dical n\u00e9erlandais:\u00ab Actuellement, <\/span>cannabis m\u00e9dicinal ne peut pas gu\u00e9rir les conditions ci-dessus. <\/span>Il peut, cependant, soulager les sympt\u00f4mes associ\u00e9s avec eux et \/ ou de r\u00e9duire les effets secondaires des autres m\u00e9dicaments. <\/span>Il appartient aux m\u00e9decins de d\u00e9terminer quelles conditions peut b\u00e9n\u00e9ficier d’un traitement avec du cannabis m\u00e9dicinal, et dans quelles circonstances il serait bon pour le patient. <\/span>De cette fa\u00e7on, ils ne sont pas limit\u00e9s \u00e0 la liste des caract\u00e9ristiques indiqu\u00e9es ci-dessus “.
\n<\/span>Ce \u00abd\u00e9cret\u00bb AIFA se verrouille en pratique le d\u00e9veloppement de la production de cannabis en Italie, quand on sait qu’il ya d\u00e9j\u00e0 un institut de recherche public, le ACRRIC de Rovigo, qui pousse des m\u00e9dicaments de haute qualit\u00e9 de cannabis. <\/span>Mais, r\u00e9guli\u00e8rement, et, paradoxalement, de livres de produits, ce qui pourrait \u00eatre utilis\u00e9 pour traiter un grand nombre de patients \u00e0 tr\u00e8s faible co\u00fbt (alors que les co\u00fbts Sativex centaines d’euros par bouteille) sont saisis par la Guardia di Finanza et d\u00e9truits.
\n<\/span>Ce \u00abd\u00e9cret\u00bb grignot\u00e9 toutes les r\u00e9gions qui ont \u00e9t\u00e9 \u00e9quip\u00e9s avec les instruments l\u00e9gislatifs appropri\u00e9s pour r\u00e9pondre aux besoins des m\u00e9decins et des patients.
\n<\/span>Ce \u00abd\u00e9cret\u00bb d\u00e9chirant des m\u00e9dicaments pour tous les patients, ne souffrant pas de scl\u00e9rose en plaques, qui ces derni\u00e8res ann\u00e9es a \u00e9t\u00e9 en mesure d’obtenir importation de cannabis m\u00e9dicinal, et se retrouvent du jour au lendemain dans l’impossibilit\u00e9 de continuer le seul traitement qui <\/span>a prouv\u00e9 son efficacit\u00e9, apr\u00e8s avoir tout essay\u00e9.
\n<\/span>Ce \u00abd\u00e9cret\u00bb Annuler espoir \u00e0 de nombreux patients atteints de maladies graves qui ne r\u00e9pondent pas aux traitements habituels, fid\u00e9istes que non, mais fond\u00e9e sur les connaissances scientifiques qui s’accumulent peu \u00e0 peu tous les jours sur le syst\u00e8me endocannabino\u00efde, qui r\u00e9gule de nombreuses fonctions de notre corps. <\/span>Esp\u00e9rons \u00e9galement bas\u00e9e sur des \u00e9tudes cliniques contr\u00f4l\u00e9es dans diff\u00e9rentes maladies, la fibromyalgie des d\u00e9g\u00e2ts de l’os, de l’\u00e9pilepsie \u00e0 la maladie d’Alzheimer pour n’en nommer que quelques-uns.
\n<\/span>Et ce \u00abd\u00e9cret\u00bb emp\u00eache les m\u00e9decins d’\u00eatre en mesure d’apporter une aide \u00e0 leurs patients et de pouvoir compter sur une arme de plus dans la lutte contre la souffrance.
\nhttp:\/\/www.medicalcannabis.it\/
\n<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"

Cannabis approvato spray per ridurre i sintomi nella sclerosi multipla copia incolla dal sito: Cannabis approvato spray contro… premesso che\u00a0 il Sativex, come gli altri farmaci cannabinoidi, non \u00e8 contro la Sclerosi Multipla e quindi non deve creare false illusioni, \u00e8 un farmaco che viene utilizzato per ridurre i sintomi del dolore\u00a0 e della spasticit\u00e0 … Continua a leggere Cannabis terapeutica: Sativex approvato…<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2,7,33],"tags":[118,284,287],"class_list":["post-1452","post","type-post","status-publish","format-standard","hentry","category-aism-2","category-cannabis-e-sclerosi-multipla","category-sclerosi-multipla-e-dintorni","tag-dolore-neuropatico","tag-sativex","tag-sclerosi-multipla"],"_links":{"self":[{"href":"https:\/\/viscontitoscoalda.com\/index.php\/wp-json\/wp\/v2\/posts\/1452","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/viscontitoscoalda.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/viscontitoscoalda.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/viscontitoscoalda.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/viscontitoscoalda.com\/index.php\/wp-json\/wp\/v2\/comments?post=1452"}],"version-history":[{"count":0,"href":"https:\/\/viscontitoscoalda.com\/index.php\/wp-json\/wp\/v2\/posts\/1452\/revisions"}],"wp:attachment":[{"href":"https:\/\/viscontitoscoalda.com\/index.php\/wp-json\/wp\/v2\/media?parent=1452"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/viscontitoscoalda.com\/index.php\/wp-json\/wp\/v2\/categories?post=1452"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/viscontitoscoalda.com\/index.php\/wp-json\/wp\/v2\/tags?post=1452"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}